Gilead Sciences – Insight Sciences

Abbott Looks to Consumer for Growth

November 12, 2008 by timbatchelder, posted in Cognitive Science, Digital health, Health Informatics, Knowledge Management, Regenerative Economy

Image representing Abbott Labs as depicted in ... — Image via CrunchBase

Abbott Looks to Consumer for Growth – WSJ.com.

Gilead Shares Rise on Hepatitis C Treatment (minyanville.com)
Hep C drugs bring high cure rates in trial (todayonline.com)
Abbott’s three oral hepatitis C drugs produce high cure rates in trial (medcitynews.com)
Abbot Holding Steady For Long-Term Investments (seekingalpha.com)
Big Corporate Breakups In 2011 (forbes.com)
Abbott admits to errors in pharma chief’s college credentials (fiercebiotech.com)
Abbott Said to Plan Benchmark Bond Offering for AbbVie Spinoff – Bloomberg (bloomberg.com)
We’ll find billions in savings: Abbott (news.theage.com.au)
Abbott Laboratories Preps Jumbo $10 Billion-Plus Bond Deal to Fund Spin-off (biospace.com)
GSK, Abbott drug combo kills triple-negative breast cancer in mice (fiercebiotechresearch.com)

Apple Science Profiles – Vertex Pharmaceuticals

August 27, 2008 by timbatchelder, posted in Cognitive Science, Design UX, Health Informatics, Knowledge Management, Linguistic Search, Metadata Masterdata, Network Science

20111230-NodeXL-Twitter-pfizer network graph — 20111230-NodeXL-Twitter-pfizer network graph (Photo credit: Marc_Smith)

Apple – Science – Profiles – Vertex Pharmaceuticals.

Vertex uses Macs.

Safety Can’t Be an Afterthought (fool.com)
Vertex (VRTX) Report Positive Data from Viral Kinetic of ALS-2200 in HCV Patients (streetinsider.com)
Big Pharma + Big Failure = Big Punishment (dailyfinance.com)
U.S. Biotech Clusters Are Losing Their Anchor Tenants, and It Hurts (xconomy.com)
Vertex Pharma (VRTX) Reports Statistically Significant Data from KALYDECO Phase 2 (streetinsider.com)
Veteran biotech investor talks of new reality (utsandiego.com)
Financings Of The Fortnight: Idenix To Forge Ahead On HCV Combo After Novartis’ Departure (invivoblog.blogspot.com)
Expert On The Amylin Purchase: ‘I Hate This Deal’ (forbes.com)
Surge in biotech deals to unlock big investor profits (news.yahoo.com)
Which Biotechs Could Be Next M&A Targets (AMLN, BMY, VRTX, CELG, CBST, AMRN, BMRN, VVUS, ARNA, PCYC, AFFX, THRX, RIGL, HGSI, GSK, DNDN) (247wallst.com)

Vertex: Planning Trial Supplies Using Tourtellotte Software

August 27, 2007 by timbatchelder, posted in Design UX, Health Informatics, Knowledge Management, Linguistic Search, Network Science

Ritalin — Ritalin (Photo credit: Wikipedia)

Vertex: Planning Trial Supplies Using Tourtellotte Software – Bio-IT World.

A Non-Earnings Boost for Vertex (fool.com)
Why You Should Be Bullish On Vertex Now (seekingalpha.com)
Vertex surges as rival hep C contender plays catch-up in clinic (fiercebiotech.com)
Bristol-Myers’ Hepatitis Stumble Boosts Gilead, Vertex (minyanville.com)
Vertex Wins EU Approval for Cystic Fibrosis Drug (xconomy.com)
Vertex Is Tomorrow’s Monster Stock (fool.com)
Slice and Dice Data and Investors Will Slice You (fool.com)
A Non-Earnings Boost for Vertex (dailyfinance.com)
An Assault On Vertex, Enthusiasm Building Around Xoma (seekingalpha.com)
After Big Oops, Vertex Plows Ahead With Cystic Fibrosis Drug Combo (xconomy.com)